Signals, Powered By EquityPandit
Lupin, the pharma major has partnered with Eli Lilly India for marketing and selling the diabetes treatment drug of Eli Lilly’s ‘Eglucent’ in the country.
Lupin ha said in a BSE filing that “According to the agreement, Lupin will market and sell Eglucent through its own specialty field force while Lilly will be responsible for manufacturing and import.”
It added that “Eli Lilly and Company (India) Pvt Ltd (Lilly) will continue to sell Lispro under the brand name Humalog through its existing channels.”
